- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2011 (2011), Article ID 647987, 7 pages
Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
Department of Urology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
Received 29 June 2011; Accepted 9 August 2011
Academic Editor: Arnulf Stenzl
Copyright © 2011 Takahiro Inoue and Osamu Ogawa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- American Cancer Society, Cancer Facts and Figures, American Cancer Society, Atlanta, Ga, USA, 2010.
- 2. Cancer Statistics in Japan, 2005, http://ganjoho.jp/public/statistics/backnumber/2005_en.html.
- C. Huggins, “Effect of orchiectomy and irradiation on cancer of the prostate,” Annals of Surgery, vol. 115, no. 6, pp. 1192–1200, 1942.
- B. J. Feldman and D. Feldman, “The development of androgen-independent prostate cancer,” Nature Reviews Cancer, vol. 1, no. 1, pp. 34–45, 2001.
- T. Inoue, T. Kobayashi, N. Terada et al., “Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells,” Expert Review of Endocrinology and Metabolism, vol. 2, no. 5, pp. 689–704, 2007.
- J. Li, C. Yen, D. Liaw et al., “PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer,” Science, vol. 275, no. 5308, pp. 1943–1947, 1997.
- D. Liaw, D. J. Marsh, J. Li et al., “Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome,” Nature Genetics, vol. 16, no. 1, pp. 64–67, 1997.
- P. A. Steck, M. A. Pershouse, S. A. Jasser et al., “Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers,” Nature Genetics, vol. 15, no. 4, pp. 356–362, 1997.
- V. Stambolic, A. Suzuki, J. L. de la Pompa et al., “Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN,” Cell, vol. 95, no. 1, pp. 29–39, 1998.
- M. M. Shen and C. Abate-Shen, “Molecular genetics of prostate cancer: new prospects for old challenges,” Genes and Development, vol. 24, no. 18, pp. 1967–2000, 2010.
- B. S. Taylor, N. Schultz, H. Hieronymus et al., “Integrative genomic profiling of human prostate cancer,” Cancer Cell, vol. 18, no. 1, pp. 11–22, 2010.
- B. Han, R. Mehra, R. J. Lonigro et al., “Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression,” Modern Pathology, vol. 22, no. 8, pp. 1083–1093, 2009.
- H. Gao, X. Ouyang, W. A. Banach-Petrosky, M. M. Shen, and C. Abate-Shen, “Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice,” Cancer Research, vol. 66, no. 16, pp. 7929–7933, 2006.
- B. Carver, C. Chapinski, J. Wongvipat et al., “Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer,” Cancer Cell, vol. 19, no. 5, pp. 575–586, 2011.
- D. Mulholland, L. Tran, Y. Li et al., “Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth,” Cancer Cell, vol. 19, no. 6, pp. 792–804, 2011.
- T. Kobayashi, Y. Shimizu, N. Terada et al., “Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation,” Prostate, vol. 70, no. 8, pp. 866–874, 2010.
- W. Zhang, J. Zhu, C. L. Efferson et al., “Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer,” Cancer Research, vol. 69, no. 18, pp. 7466–7472, 2009.
- A. Schayowitz, G. Sabnis, O. Goloubeva, V. C. O. Njar, and A. M. H. Brodie, “Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR,” British Journal of Cancer, vol. 103, no. 7, pp. 1001–1007, 2010.
- Y. Nishizuka, “Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C,” Science, vol. 258, no. 5082, pp. 607–614, 1992.
- Y. Nishizuka, “Protein kinase C and lipid signaling for sustained cellular responses,” The FASEB Journal, vol. 9, no. 7, pp. 484–496, 1995.
- J. Koivunen, V. Aaltonen, and J. Peltonen, “Protein kinase C (PKC) family in cancer progression,” Cancer Letters, vol. 235, no. 1, pp. 1–10, 2006.
- M. Castagna, Y. Takai, and K. Kaibuchi, “Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters,” The Journal of Biological Chemistry, vol. 257, no. 13, pp. 7847–7851, 1982.
- E. Metzger, A. Imhof, D. Patel et al., “Phosphorylation of histone H3T6 by PKC i controls demethylation at histone H3K4,” Nature, vol. 464, no. 7289, pp. 792–796, 2010.
- B. B. Hafeez, W. Zhong, J. Weichert, N. E. Dreckschmidt, M. S. Jamal, and A. K. Verma, “Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma,” Cancer Research, vol. 71, no. 6, pp. 2318–2327, 2011.
- F. Benavides, J. Blando, C. J. Perez et al., “Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions,” Cell Cycle, vol. 10, no. 2, pp. 268–277, 2011.
- J. Moscat, M. T. Diaz-Meco, and M. W. Wooten, “Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex,” Cell Death and Differentiation, vol. 16, no. 11, pp. 1426–1437, 2009.
- I. García-Cao, A. Duran, M. Collado et al., “Tumour-suppression activity of the proapoptotic regulator Par4,” EMBO Reports, vol. 6, no. 6, pp. 577–583, 2005.
- P. J. Fernandez-Marcos, S. Abu-Baker, J. Joshi et al., “Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-κB activation and invasive prostate carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 12962–12967, 2009.
- T. Inoue, T. Yoshida, Y. Shimizu et al., “Requirement of androgen-dependent activation of protein kinase Cζ for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells,” Molecular Endocrinology, vol. 20, no. 12, pp. 3053–3069, 2006.
- T. Kobayashi, T. Inoue, Y. Shimizu et al., “Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo,” Molecular Endocrinology, vol. 24, no. 4, pp. 722–734, 2010.
- H. Ishiguro, K. Akimoto, Y. Nagashima et al., “aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16369–16374, 2009.
- S. Yao, A. Bee, D. Brewer, et al., “PRKC- expression promotes the aggressive phenotype of human prostate cancer cells is a novel target for therapeutic intervention,” Genes and Cancer, vol. 1, no. 5, pp. 444–464, 2010.
- A. M. De Marzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269, 2007.
- S. Mahmud, E. Franco, and A. Aprikian, “Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis,” British Journal of Cancer, vol. 90, no. 1, pp. 93–99, 2004.
- A. V. Krishnan and D. Feldman, “Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R19–R38, 2010.
- A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008.
- D. G. Menter, R. L. Schilsky, and R. N. DuBois, “Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward,” Clinical Cancer Research, vol. 16, no. 5, pp. 1384–1390, 2010.
- W. A. Ray, C. M. Stein, J. R. Daugherty, K. Hall, P. G. Arbogast, and M. R. Griffin, “COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease,” The Lancet, vol. 360, no. 9339, pp. 1071–1073, 2002.
- Y. Sugimoto and S. Narumiya, “Prostaglandin E receptors,” The Journal of Biological Chemistry, vol. 282, no. 16, pp. 11613–11617, 2007.
- M. Sonoshita, K. Takaku, N. Sasaki et al., “Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice,” Nature Medicine, vol. 7, no. 9, pp. 1048–1051, 2001.
- S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu, “Prostaglandin E2 regulates tumor angiogenesis in prostate cancer,” Cancer Research, vol. 68, no. 19, pp. 7750–7759, 2008.
- T. Yoshida, H. Kinoshita, T. Segawa et al., “Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient,” Cancer Research, vol. 65, no. 21, pp. 9611–9616, 2005.
- N. Terada, Y. Shimizu, T. Kamba et al., “Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model,” Cancer Research, vol. 70, no. 4, pp. 1606–1615, 2010.
- R. Hu, T. A. Dunn, S. Wei et al., “Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer,” Cancer Research, vol. 69, no. 1, pp. 16–22, 2009.
- Z. Guo, X. Yang, F. Sun et al., “A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth,” Cancer Research, vol. 69, no. 6, pp. 2305–2313, 2009.
- S. Sun, C. C. T. Sprenger, R. L. Vessella et al., “Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant,” The Journal of Clinical Investigation, vol. 120, no. 8, pp. 2715–2730, 2010.
- P. A. Watson, Y. F. Chen, M. D. Balbas et al., “Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 39, pp. 16759–16765, 2010.
- K. R. Lamont and D. J. Tindall, “Minireview: alternative activation pathways for the androgen receptor in prostate cancer,” Molecular Endocrinology, vol. 25, no. 6, pp. 897–907, 2011.
- O. Tatarov, T. J. Mitchell, M. Seywright, H. Y. Leung, V. G. Brunton, and J. Edwards, “Src family kinase activity is up-regulated in hormone-refractory prostate cancer,” Clinical Cancer Research, vol. 15, no. 10, pp. 3540–3549, 2009.
- Z. Guo, B. Dai, T. Jiang et al., “Regulation of androgen receptor activity by tyrosine phosphorylation,” Cancer Cell, vol. 10, no. 4, pp. 309–319, 2006.
- T. J. Yeatman, “A renaissance for SRC,” Nature Reviews Cancer, vol. 4, no. 6, pp. 470–480, 2004.
- H. Cai, I. Babic, X. Wei, J. Huang, and O. N. Witte, “Invasive prostate carcinoma driven by c-Src and androgen receptor synergy,” Cancer Research, vol. 71, no. 3, pp. 862–872, 2011.
- M. Karlou, V. Tzelepi, and E. Efstathiou, “Therapeutic targeting of the prostate cancer microenvironment,” Nature Reviews Urology, vol. 7, no. 9, pp. 494–509, 2010.
- D. L. Burkhart and J. Sage, “Cellular mechanisms of tumour suppression by the retinoblastoma gene,” Nature Reviews Cancer, vol. 8, no. 9, pp. 671–682, 2008.
- A. Sharma, W. S. Yeow, A. Ertel et al., “The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression,” The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4478–4492, 2010.
- S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005.
- R. S. Mani and A. M. Chinnaiyan, “Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences,” Nature Reviews Genetics, vol. 11, no. 12, pp. 819–829, 2010.
- R. S. Mani, S. A. Tomlins, K. Callahan et al., “Induced chromosomal proximity and gene fusions in prostate cancer,” Science, vol. 326, no. 5957, article 1230, p. 1230, 2009.
- J. C. King, J. Xu, J. Wongvipat et al., “Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis,” Nature Genetics, vol. 41, no. 5, pp. 524–526, 2009.
- B. S. Carver, J. Tran, A. Gopalan et al., “Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate,” Nature Genetics, vol. 41, no. 5, pp. 619–624, 2009.
- J. Yu, J. Yu, R. S. Mani et al., “An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression,” Cancer Cell, vol. 17, no. 5, pp. 443–454, 2010.
- P. Kunderfranco, M. Mello-Grand, R. Cangemi et al., “ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer,” PloS one, vol. 5, no. 5, Article ID e10547, 2010.